FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Dateline City: KENILWORTH, N.J. Filing Receives Priority Review KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as…